IL326176A - תיוליפידים הניתנים ליינון ושימושים בהם - Google Patents
תיוליפידים הניתנים ליינון ושימושים בהםInfo
- Publication number
- IL326176A IL326176A IL326176A IL32617626A IL326176A IL 326176 A IL326176 A IL 326176A IL 326176 A IL326176 A IL 326176A IL 32617626 A IL32617626 A IL 32617626A IL 326176 A IL326176 A IL 326176A
- Authority
- IL
- Israel
- Prior art keywords
- thiolipids
- ionizable
- ionizable thiolipids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
- C07C311/32—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
- C07C335/08—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/21—Radicals derived from sulfur analogues of carbonic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2023/071270 WO2025026545A1 (en) | 2023-08-01 | 2023-08-01 | Ionizable thioplipids and uses thereof |
| US202463639459P | 2024-04-26 | 2024-04-26 | |
| PCT/EP2024/071710 WO2025027089A1 (en) | 2023-08-01 | 2024-07-31 | Ionizable thiolipids and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL326176A true IL326176A (he) | 2026-03-01 |
Family
ID=92708884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL326176A IL326176A (he) | 2023-08-01 | 2024-07-31 | תיוליפידים הניתנים ליינון ושימושים בהם |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4731606A1 (he) |
| CN (1) | CN121646579A (he) |
| AU (1) | AU2024315222A1 (he) |
| IL (1) | IL326176A (he) |
| TW (1) | TW202519509A (he) |
| WO (1) | WO2025027089A1 (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025176732A1 (en) | 2024-02-20 | 2025-08-28 | BioNTech SE | Compositions and methods |
| WO2025228975A1 (en) | 2024-04-29 | 2025-11-06 | BioNTech SE | Particles, compositions and methods |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3556323B2 (ja) | 1995-06-15 | 2004-08-18 | 富士通株式会社 | 中継装置 |
| US5965542A (en) | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
| JP2002502831A (ja) | 1998-02-03 | 2002-01-29 | イネックス ファーマシューティカルズ コーポレイション | 癌の治療に用いる血清に対して安定なプラスミド脂質粒子の全身供与 |
| US6410328B1 (en) | 1998-02-03 | 2002-06-25 | Protiva Biotherapeutics Inc. | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
| US6211140B1 (en) | 1999-07-26 | 2001-04-03 | The Procter & Gamble Company | Cationic charge boosting systems |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| ES2559828T3 (es) | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
| US6927663B2 (en) | 2003-07-23 | 2005-08-09 | Cardiac Pacemakers, Inc. | Flyback transformer wire attach method to printed circuit board |
| NZ592917A (en) | 2003-09-15 | 2012-12-21 | Protiva Biotherapeutics Inc | Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
| US9005654B2 (en) | 2005-07-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Systems and methods for manufacturing liposomes |
| EP3611266B1 (en) | 2005-08-23 | 2022-11-09 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| HUE037082T2 (hu) | 2008-11-10 | 2018-08-28 | Arbutus Biopharma Corp | Új lipidek és készítmények terápiás hatóanyagok szállítására |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| EP2506879A4 (en) | 2009-12-01 | 2014-03-19 | Protiva Biotherapeutics Inc | PREPARATIONS OF SNALP CONTAINING ANTIOXIDANTS |
| WO2011071860A2 (en) | 2009-12-07 | 2011-06-16 | Alnylam Pharmaceuticals, Inc. | Compositions for nucleic acid delivery |
| CA2784568A1 (en) | 2009-12-18 | 2011-06-23 | The University Of British Columbia | Lipid particles for delivery of nucleic acids |
| WO2011141705A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
| SG186085A1 (en) | 2010-06-03 | 2013-01-30 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
| EP2760477B1 (en) | 2011-09-27 | 2018-08-08 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
| US8762704B2 (en) | 2011-09-29 | 2014-06-24 | Apple Inc. | Customized content for electronic devices |
| US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| EP2788316B1 (en) | 2011-12-07 | 2019-04-24 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
| EP2788006B1 (en) | 2011-12-07 | 2026-01-07 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| WO2014008334A1 (en) | 2012-07-06 | 2014-01-09 | Alnylam Pharmaceuticals, Inc. | Stable non-aggregating nucleic acid lipid particle formulations |
| SMT202200502T1 (it) | 2014-06-25 | 2023-01-13 | Acuitas Therapeutics Inc | Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici |
| EP2966068A1 (en) * | 2014-07-08 | 2016-01-13 | Incella GmbH | Synthesis and use of amino lipids |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| LT3313829T (lt) | 2015-06-29 | 2024-08-12 | Acuitas Therapeutics Inc. | Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui |
| JP7078812B2 (ja) | 2015-08-28 | 2022-06-01 | バイオンテック・エスイー | Ｒｎａの免疫原性を低減するための方法 |
| ES2964690T3 (es) | 2015-09-21 | 2024-04-09 | Trilink Biotechnologies Llc | Método para sintetizar ARN con caperuza 5' |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| IL307179A (he) | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | ליפידים חדשים ופורמולציות ננוחלקיקים של ליפידים למתן חומצות גרעין |
| WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| ES3063077T3 (en) | 2016-10-26 | 2026-04-15 | Acuitas Therapeutics Inc | Lipid nanoparticle formulations |
| EP3573619A4 (en) | 2017-01-27 | 2020-10-28 | SignalRX Pharmaceuticals, Inc. | THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN AND CHECKPOINT INHIBITORS |
| EP3662913A4 (en) * | 2017-08-04 | 2021-06-30 | Kyowa Kirin Co., Ltd. | Nucleic-acid-containing lipid nanoparticles |
| CA3150061A1 (en) * | 2019-08-07 | 2021-02-11 | Modernatx, Inc. | Compositions and methods for enhanced delivery of agents |
| AU2021288987A1 (en) | 2020-06-10 | 2023-02-09 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of MCL-1 |
| CN113461577B (zh) * | 2021-09-01 | 2021-12-14 | 中山大学附属第七医院(深圳) | 一种氨基脂质及其应用 |
| CN114989027B (zh) * | 2022-08-03 | 2023-01-31 | 深圳市瑞吉生物科技有限公司 | 用于递送核酸的阳离子脂质化合物和组合物及用途 |
-
2024
- 2024-07-31 IL IL326176A patent/IL326176A/he unknown
- 2024-07-31 CN CN202480050485.7A patent/CN121646579A/zh active Pending
- 2024-07-31 EP EP24767995.4A patent/EP4731606A1/en active Pending
- 2024-07-31 AU AU2024315222A patent/AU2024315222A1/en active Pending
- 2024-07-31 WO PCT/EP2024/071710 patent/WO2025027089A1/en active Pending
- 2024-07-31 TW TW113128599A patent/TW202519509A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4731606A1 (en) | 2026-04-29 |
| CN121646579A (zh) | 2026-03-10 |
| AU2024315222A1 (en) | 2026-02-05 |
| TW202519509A (zh) | 2025-05-16 |
| WO2025027089A1 (en) | 2025-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL296357B1 (he) | תרכובות פירימידו הטרוציקליות ושימושיהן | |
| IL316531A (he) | תרכובות ושימושים בהן | |
| IL326176A (he) | תיוליפידים הניתנים ליינון ושימושים בהם | |
| IL295102B2 (he) | פורמולציות ושימושיהן | |
| GB202204964D0 (en) | Superpixel generatioion and use | |
| GB202002010D0 (en) | Microtopographies and uses thereof | |
| EP4165049A4 (en) | ISOTRYPTAMIN PSYCOPLASTIOGENS AND USES THEREOF | |
| IL315356A (he) | ליפידים בעלי יכולת ינון וקומפוזיציות המכילות אותם | |
| AU2023413250A1 (en) | Ionizable lipid and use thereof | |
| GB202004094D0 (en) | New compounds and uses | |
| GB202411091D0 (en) | Compositions and uses | |
| GB202211784D0 (en) | Methods and uses | |
| IL311521A (he) | תרכובות הממוקדות egfrviii ושימושיהן | |
| CA3299724A1 (en) | Ionizable thiolipids and uses thereof | |
| GB202001570D0 (en) | Biomarkers and uses thereof | |
| GB202414155D0 (en) | De-palletiser and palletiser | |
| GB202216802D0 (en) | V-easdf and ipups | |
| GB2625512B (en) | Triggered-producer and triggered-consumer instructions | |
| GB202213714D0 (en) | Devices and uses thereof | |
| GB202300520D0 (en) | Methods and uses | |
| GB202304356D0 (en) | Peptides and uses thereof | |
| GB202312279D0 (en) | New compounds and uses | |
| GB202203804D0 (en) | Uses and methods | |
| GB202314282D0 (en) | New compounds and uses thereof | |
| GB202312176D0 (en) | New uses and methods |